PCSK9 outcome trials: The results put into perspective of other clinical developments
PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.
Video navigation menu
Is it safe to go down that low and is there additional benefit from this LDL-c lowering? 00:53
Would we have expected more, given the magnitude of LDL-c reduction? 01:43
Who is eligible for these drugs? 02:20
How to put the results of FOURIER into perspective of other trials and molecules? 03:47
Insights on the effect on neurocognition in the EBBINGHAUS substudy 05:58
Educational information
This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice
The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME
Disclosures
Prof. Peter Sever - National Heart & Lung Institute, Imperial College London, United Kingdom
Funding
Funding was provided by an unrestricted educational grant from Amgen
Share this page with your colleagues and friends: